Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014, Article ID 765784, 9 pages
http://dx.doi.org/10.1155/2014/765784
Research Article

Insulin Increases Ceramide Synthesis in Skeletal Muscle

1Department of Physiology and Developmental Biology, 593 WIDB, Brigham Young University, Provo, UT 84602, USA
2Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84602, USA

Received 18 March 2014; Revised 15 April 2014; Accepted 22 April 2014; Published 18 May 2014

Academic Editor: Konstantinos Papatheodorou

Copyright © 2014 M. E. Hansen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. J. Pories and G. L. Dohm, “Diabetes: have we got it all wrong? Hyperinsulinism as the culprit: surgery provides the evidence,” Diabetes Care, vol. 35, no. 12, pp. 2438–2442, 2012. View at Publisher · View at Google Scholar
  2. G. M. Reaven, C. Hollenbeck, C.-Y. Jeng, M. S. Wu, and Y.-D. I. Chen, “Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM,” Diabetes, vol. 37, no. 8, pp. 1020–1024, 1988. View at Google Scholar · View at Scopus
  3. A. K. Das and S. Shah, “History of diabetes: from ants to analogs,” The Journal of the Association of Physicians of India, vol. 59, pp. 6–7, 2011. View at Google Scholar · View at Scopus
  4. J. D. McGarry, “What if Minkowski had been ageusic? An alternative angle on diabetes,” Science, vol. 258, no. 5083, pp. 766–770, 1992. View at Google Scholar · View at Scopus
  5. J. A. Chavez and S. A. Summers, “Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms,” Biochimica et Biophysica Acta, vol. 1801, no. 3, pp. 252–265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. H. Shanik, Y. Xu, J. Skrha, R. Dankner, Y. Zick, and J. Roth, “Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?” Diabetes Care, vol. 31, supplement 2, pp. S262–S268, 2008. View at Google Scholar · View at Scopus
  7. C. J. Currie, J. R. Peters, A. Tynan et al., “Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study,” The Lancet, vol. 375, no. 9713, pp. 481–489, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Ferrannini, G. Buzzigoli, R. Bonadonna et al., “Insulin resistance in essential hypertension,” The New England Journal of Medicine, vol. 317, no. 6, pp. 350–357, 1987. View at Google Scholar
  9. K. M. Utzschneider and S. E. Kahn, “Review: the role of insulin resistance in nonalcoholic fatty liver disease,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 12, pp. 4753–4761, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. B. T. Bikman and S. A. Summers, “Sphingolipids and hepatic steatosis,” Advances in Experimental Medicine and Biology, vol. 721, pp. 87–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Dunaif, “Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis,” Endocrine Reviews, vol. 18, no. 6, pp. 774–800, 1997. View at Google Scholar
  12. G. S. Watson and S. Craft, “The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment,” CNS Drugs, vol. 17, no. 1, pp. 27–45, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Murakami, Y. Shigematsu, M. Hamada, and J. Higaki, “Insulin resistance in patients with hypertrophic cardiomyopthy,” Circulation Journal, vol. 68, no. 7, pp. 650–655, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Guillet and Y. Boirie, “Insulin resistance: a contributing factor to age-related muscle mass loss?” Diabetes & Metabolism, vol. 31, no. 2, pp. S20–S26, 2005. View at Google Scholar · View at Scopus
  15. R. A. DeFronzo and E. Ferrannini, “Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease,” Diabetes Care, vol. 14, no. 3, pp. 173–194, 1991. View at Google Scholar · View at Scopus
  16. J. M. Haus, S. R. Kashyap, T. Kasumov et al., “Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance,” Diabetes, vol. 58, no. 2, pp. 337–343, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. L. J. A. Spijkers, R. F. P. van den Akker, B. J. A. Janssen et al., “Hypertension is associated with marked alterations in sphingolipid biology: a potential role for ceramide,” PLoS ONE, vol. 6, no. 7, Article ID e21817, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Marks, M. J. Berg, M. Saito, and M. Saito, “Glucosylceramide synthase decrease in frontal cortex of Alzheimer brain correlates with abnormal increase in endogenous ceramides: consequences to morphology and viability on enzyme suppression in cultured primary neurons,” Brain Research, vol. 1191, pp. 136–147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. R. G. Cutler, J. Kelly, K. Storie et al., “Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 7, pp. 2070–2075, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. W. L. Holland, B. T. Bikman, L.-P. Wang et al., “Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice,” The Journal of Clinical Investigation, vol. 121, no. 5, pp. 1858–1870, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. W. L. Holland, J. T. Brozinick, L.-P. Wang et al., “Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance,” Cell Metabolism, vol. 5, no. 3, pp. 167–179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. J. W. Hill, C. F. Elias, M. Fukuda et al., “Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility,” Cell Metabolism, vol. 11, no. 4, pp. 286–297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. E. Smith, T. S. Tippetts, E. S. Brassfield et al., “Mitochondrial fission mediates ceramide-induced metabolic disruption in skeletal muscle,” The Biochemical Journal, vol. 456, pp. 427–439, 2013. View at Publisher · View at Google Scholar
  24. B. T. Bikman and S. A. Summers, “Ceramides as modulators of cellular and whole-body metabolism,” The Journal of Clinical Investigation, vol. 121, no. 11, pp. 4222–4230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. B. T. Bikman, “A role for sphingolipids in the pathophysiology of obesity-induced inflammation. Cellular and molecular life sciences,” Cellular and Molecular Life Sciences, vol. 69, no. 13, pp. 2135–2146, 2012. View at Publisher · View at Google Scholar
  26. S. R. Commerford, L. Peng, J. J. Dubé, and R. M. O'Doherty, “In vivo regulation of SREBP-1c in skeletal muscle: effects of nutritional status, glucose, insulin, and leptin,” American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 287, no. 1, pp. R218–R227, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Guillet-Deniau, V. Mieulet, S. L. Lay et al., “Sterol regulatory element binding protein-1c expression and action in rat muscles: Insulin-like effects on the control of glycolytic and lipogenic enzymes and UCP3 gene expression,” Diabetes, vol. 51, no. 6, pp. 1722–1728, 2002. View at Google Scholar · View at Scopus
  28. K. Srinivasan and P. Ramarao, “Animal models in type 2 diabetes research: an overview,” The Indian Journal of Medical Research, vol. 125, no. 3, pp. 451–472, 2007. View at Google Scholar · View at Scopus
  29. D. A. Fraser, J. Thoen, A. C. Rustan, Ø. Førre, and J. Kjeldsen-Kragh, “Changes in plasma free fatty acid concentrations in rheumatoid arthritis patients during fasting and their effects upon T-lymphocyte proliferation,” Rheumatology, vol. 38, no. 10, pp. 948–952, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Fahy, S. Subramaniam, R. C. Murphy et al., “Update of the LIPID MAPS comprehensive classification system for lipids,” Journal of Lipid Research, vol. 50, pp. S9–S14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. K. A. Erickson, M. E. Smith, T. S. Anthonymuthu et al., “AICAR inhibits ceramide biosynthesis in skeletal muscle,” Diabetology & Metabolic Syndrome, vol. 4, no. 1, article 45, 2012. View at Publisher · View at Google Scholar
  32. M. W. Pfaffl, “A new mathematical model for relative quantification in real-time RT-PCR,” Nucleic Acids Research, vol. 29, no. 9, article e45, 2001. View at Google Scholar · View at Scopus
  33. B. T. Bikman, Y. Guan, G. Shui et al., “Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis,” The Journal of Biological Chemistry, vol. 287, no. 21, pp. 17426–17437, 2012. View at Publisher · View at Google Scholar
  34. J. M. Adams II, T. Pratipanawatr, R. Berria et al., “Ceramide content is increased in skeletal muscle from obese insulin-resistant humans,” Diabetes, vol. 53, no. 1, pp. 25–31, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Straczkowski, I. Kowalska, M. Baranowski et al., “Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes,” Diabetologia, vol. 50, no. 11, pp. 2366–2373, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. P. M. Coen, J. J. Dubé, F. Amati et al., “Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content,” Diabetes, vol. 59, no. 1, pp. 80–88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. J. A. Chavez, T. A. Knotts, L.-P. Wang et al., “A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids,” The Journal of Biological Chemistry, vol. 278, no. 12, pp. 10297–10303, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Schmitz-Peiffer, D. L. Craig, and T. J. Biden, “Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate,” The Journal of Biological Chemistry, vol. 274, no. 34, pp. 24202–24210, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Amati, J. J. Dubé, E. Alvarez-Carnero et al., “Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes?” Diabetes, vol. 60, no. 10, pp. 2588–2597, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. W. L. Holland, R. A. Miller, Z. V. Wang et al., “Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin,” Nature Medicine, vol. 17, no. 1, pp. 55–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Zabielski, A. U. Blachnio-Zabielska, I. R. Lanza et al., “Impact of insulin deprivation and treatment on sphingolipid distribution in different muscle subcellular compartments of streptozotocin-diabetic C57Bl/6 mice,” American Journal of Physiology Endocrinology and Metabolism, 2013. View at Publisher · View at Google Scholar
  42. B. H. Goodpaster, J. He, S. Watkins, and D. E. Kelley, “Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 12, pp. 5755–5761, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Liu, Y. Zhang, N. Chen, X. Shi, B. Tsang, and Y.-H. Yu, “Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance,” The Journal of Clinical Investigation, vol. 117, no. 6, pp. 1679–1689, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. J. A. Lopez-Velazquez, L. D. Carrillo-Cordova, N. C. Chavez-Tapia, M. Uribe, and N. Mendez-Sanchez, “Nuclear receptors in nonalcoholic Fatty liver disease,” Journal of Lipids, vol. 2012, Article ID 139875, 10 pages, 2012. View at Publisher · View at Google Scholar
  45. S. Li, M. S. Brown, and J. L. Goldstein, “Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 8, pp. 3441–3446, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. F. S. Facchini, N. Hua, F. Abbasi, and G. M. Reaven, “Insulin resistance as a predictor of age-related diseases,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 8, pp. 3574–3578, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Deckert, J. E. Poulsen, and M. Larsen, “Prognosis of diabetics with diabetes onset before the age of thirtyone. II. Factors influencing the prognosis,” Diabetologia, vol. 14, no. 6, pp. 371–377, 1978. View at Google Scholar · View at Scopus
  48. G. S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M. F. White, and B. M. Spiegelman, “IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance,” Science, vol. 271, no. 5249, pp. 665–668, 1996. View at Publisher · View at Google Scholar
  49. P. A. Velasquez-Mieyer, P. A. Cowan, K. L. Arheart et al., “Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults,” International Journal of Obesity, vol. 27, no. 2, pp. 219–226, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. B. M. King, R. L. Smith, and L. A. Frohman, “Hyperinsulinemia in rats with ventromedial hypothalamic lesions: role of hyperphagia,” Behavioral Neuroscience, vol. 98, no. 1, pp. 152–155, 1984. View at Publisher · View at Google Scholar · View at Scopus
  51. B. E. Hustvedt and A. Lovo, “Correlation between hyperinsulinemia and hyperphagia in rats with ventromedial hypothalamic lesions,” Acta Physiologica Scandinavica, vol. 84, no. 1, pp. 29–33, 1972. View at Google Scholar · View at Scopus
  52. M. G. Carlson and P. J. Campbell, “Intensive insulin therapy and weight gain in IDDM,” Diabetes, vol. 42, no. 12, pp. 1700–1707, 1993. View at Google Scholar · View at Scopus
  53. S. Mäkimattila, K. Nikkilä, and H. Yki-Järvinen, “Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus,” Diabetologia, vol. 42, no. 4, pp. 406–412, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Torbay, E. F. Bracco, A. Geliebter, I. M. Stewart, and S. A. Hashim, “Insulin increases body fat despite control of food intake and physical activity,” The American Journal of Physiology, vol. 248, no. 1, part 2, pp. R120–R124, 1985. View at Google Scholar · View at Scopus
  55. J. E. Cox and T. L. Powley, “Development of obesity in diabetic mice pair fed with lean siblings,” Journal of Comparative and Physiological Psychology, vol. 91, no. 2, pp. 347–358, 1977. View at Google Scholar · View at Scopus
  56. D. M. Nathan, J. B. Buse, M. B. Davidson et al., “Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, vol. 32, no. 1, pp. 193–203, 2009. View at Publisher · View at Google Scholar
  57. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, supplement 1, pp. S62–S69, 2010. View at Publisher · View at Google Scholar
  58. W. S. Yancy Jr., M. Foy, A. M. Chalecki, M. C. Vernon, and E. C. Westman, “A low-carbohydrate, ketogenic diet to treat type 2 diabetes,” Nutrition & Metabolism, vol. 2, article 34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. R. W. Stout, “Insulin-stimulated lipogenesis in arterial tissue in relation to diabetes and atheroma,” The Lancet, vol. 2, no. 7570, pp. 702–703, 1968. View at Google Scholar · View at Scopus
  60. J. Bismuth, P. Lin, Q. Yao, and C. Chen, “Ceramide: a common pathway for atherosclerosis?” Atherosclerosis, vol. 196, no. 2, pp. 497–504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. G. M. Reaven, H. Lithell, and L. Landsberg, “Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system,” The New England Journal of Medicine, vol. 334, no. 6, pp. 374–381, 1996. View at Publisher · View at Google Scholar
  62. D. X. Zhang, A.-P. Zou, and P.-L. Li, “Ceramide reduces endothelium-dependent vasodilation by increasing superoxide production in small bovine coronary arteries,” Circulation Research, vol. 88, no. 8, pp. 824–831, 2001. View at Google Scholar · View at Scopus
  63. Q. J. Zhang, W. L. Holland, L. Wilson et al., “Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex,” Diabetes, vol. 61, no. 7, pp. 1848–1859, 2012. View at Publisher · View at Google Scholar